国家 | Canada |
---|---|
成立时间 | 2015 |
总部 | 661 University Ave, Toronto, Ontario CA |
电话号码 | +1 888-613-6862 |
网站 | http://www.pancella.com |
http://www.linkedin.com/company/pancella | |
https://twitter.com/pancellainc | |
https://www.facebook.com/panCELLaInc | |
员工数 | 9 |
行业 | research, |
简介 | Co-founded in 2015 by Dr. Andras Nagy, PhD, and Dr. Armand Keating, MD, PhD,. The expertise represented by the co-founders were a perfect combination to create a unique conceptual framework for a company aiming to move cell therapy to broad clinical applications. panCELLa has created platforms that allow for the development of safe, universal, cost-effective, "off-the-shelf" therapeutic cell products for medicine. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive FailSafe® and Stealth Cells®, and its in-licensed SAFE harbor technology. panCELLa continues its internal R&D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination and tolerization. In October 2022 Pluristyx announced a merger with panCELLa. PanCELLa today offers an array of unique and effective technologies with particular strength in gene editing, while Pluristyx offers a portfolio of induced Pluripotent Stem Cell (iPSC)-based products and services to provide end-to-end client support in early product development. As one company, panCELLa and Pluristyx offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, "off-the-shelf" iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization. |